Michael C. Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael C. Jin has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Ash A. Alizadeh
Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, USA
22 shared publications - David M. Kurtz
Stanford University School of Medicine, Stanford, CA
21 shared publications - Chih Long Liu
Stanford Cancer Institute, Stanford University, Stanford, USA
20 shared publications - Florian Scherer
Department of Medicine I, Medical Center—University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany
20 shared publications - Maximilian Diehn
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, USA
20 shared publications - Agnès Bru
From the Immunoconcept (M.N.K., A.D., I.H., A.B., N.S.), CNRS UMR 5164, University of Bordeaux; Service de Neurologie (M.D., A.R.), CRC SEP, Centre Hospitalier Universitaire (CHU) de Bordeaux; and INSERM U 1215 (B.B., A.R.), Neurocentre Magendie, University of Bordeaux, France
19 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S15 from Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors
Supplementary Table S1. Patient and control clinical characteristics Supplementary Table S2. Sequencing metrics for FL cases & controls Supplementary Table S3. Identified mutations in EPIC FL pre-diagnostic samples Supplementary Table S4. Identified mutations in control samples Supplementary Table S5. Statistical significance for detection in prediagnostic samples with paired tumor biopsy Supplementary Table S6. Identified mutations in FL tumors with detection in paired prediagnostic samples Supplementary Table S7. Paired tumor cohort histology & sample characteristics Supplementary Table S8. Identified mutations in paired biopsy samples Supplementary Table S9. Clonal VDJ rearrangements in paired biopsies Supplementary Table S10. Concordance analysis of paired biopsy samples Supplementary Table S11. Patient characteristics, marrow and sorting studies Supplementary Table S12. DNA and sequencing metrics for marrow and sorting studies Supplementary Table S13. Monoclonal antibodies and manufacturers Supplementary Table S14. Mutations detected in marrow and sorting studies Supplementary Table S15. Genes fully or partially covered in lymphoma-focused CAPP-Seq selector
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S15 from Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors
Supplementary Table S1. Patient and control clinical characteristics Supplementary Table S2. Sequencing metrics for FL cases & controls Supplementary Table S3. Identified mutations in EPIC FL pre-diagnostic samples Supplementary Table S4. Identified mutations in control samples Supplementary Table S5. Statistical significance for detection in prediagnostic samples with paired tumor biopsy Supplementary Table S6. Identified mutations in FL tumors with detection in paired prediagnostic samples Supplementary Table S7. Paired tumor cohort histology & sample characteristics Supplementary Table S8. Identified mutations in paired biopsy samples Supplementary Table S9. Clonal VDJ rearrangements in paired biopsies Supplementary Table S10. Concordance analysis of paired biopsy samples Supplementary Table S11. Patient characteristics, marrow and sorting studies Supplementary Table S12. DNA and sequencing metrics for marrow and sorting studies Supplementary Table S13. Monoclonal antibodies and manufacturers Supplementary Table S14. Mutations detected in marrow and sorting studies Supplementary Table S15. Genes fully or partially covered in lymphoma-focused CAPP-Seq selector
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods & Figures S1-S5 from Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors
Supplementary Methods and Figures S1-S5
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods & Figures S1-S5 from Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors
Supplementary Methods and Figures S1-S5
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors
Follicular lymphomas (FL) are characterized by BCL2 translocations, often detectable in blood years before FL diagnosis, but also observed in aging healthy individuals, suggesting additional lesions are required for lymphomagenesis. We directly characterized early cooperating mutations by ultradeep sequencing of prediagnostic blood and tissue specimens from 48 subjects who ultimately developed FL. Strikingly, CREBBP lysine acetyltransferase (KAT) domain mutations were the most commonly observed precursor lesions, and largely distinguished patients developing FL (14/48, 29%) from healthy adults with or without detected BCL2 rearrangements (0/13, P = 0.03 and 0/20, P = 0.007, respectively). CREBBP variants were detectable a median of 5.8 years before FL diagnosis, were clonally selected in FL tumors, and appeared restricted to the committed B-cell lineage. These results suggest that mutations affecting the CREBBP KAT domain are common lesions in FL cancer precursor cells (CPC), with the potential for discriminating subjects at risk of developing FL or monitoring residual disease.Significance:Our study provides direct evidence for recurrent genetic aberrations preceding FL diagnosis, revealing the combination of BCL2 translocation with CREBBP KAT domain mutations as characteristic committed lesions of FL CPCs. Such prediagnostic mutations are detectable years before clinical diagnosis and may help discriminate individuals at risk for lymphoma development.This article is highlighted in the In This Issue feature, p. 1275
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors
Follicular lymphomas (FL) are characterized by BCL2 translocations, often detectable in blood years before FL diagnosis, but also observed in aging healthy individuals, suggesting additional lesions are required for lymphomagenesis. We directly characterized early cooperating mutations by ultradeep sequencing of prediagnostic blood and tissue specimens from 48 subjects who ultimately developed FL. Strikingly, CREBBP lysine acetyltransferase (KAT) domain mutations were the most commonly observed precursor lesions, and largely distinguished patients developing FL (14/48, 29%) from healthy adults with or without detected BCL2 rearrangements (0/13, P = 0.03 and 0/20, P = 0.007, respectively). CREBBP variants were detectable a median of 5.8 years before FL diagnosis, were clonally selected in FL tumors, and appeared restricted to the committed B-cell lineage. These results suggest that mutations affecting the CREBBP KAT domain are common lesions in FL cancer precursor cells (CPC), with the potential for discriminating subjects at risk of developing FL or monitoring residual disease.Significance:Our study provides direct evidence for recurrent genetic aberrations preceding FL diagnosis, revealing the combination of BCL2 translocation with CREBBP KAT domain mutations as characteristic committed lesions of FL CPCs. Such prediagnostic mutations are detectable years before clinical diagnosis and may help discriminate individuals at risk for lymphoma development.This article is highlighted in the In This Issue feature, p. 1275
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Methods & Figures S1-S5 from Tracing founder mutations in circulating and tissue-resident follicular lymphoma precursors
Supplementary Methods and Figures S1-S5
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods & Figures S1-S5 from Tracing founder mutations in circulating and tissue-resident follicular lymphoma precursors
Supplementary Methods and Figures S1-S5
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S15 from Tracing founder mutations in circulating and tissue-resident follicular lymphoma precursors
Supplementary Table S1. Patient and control clinical characteristics Supplementary Table S2. Sequencing metrics for FL cases & controls Supplementary Table S3. Identified mutations in EPIC FL pre-diagnostic samples Supplementary Table S4. Identified mutations in control samples Supplementary Table S5. Statistical significance for detection in prediagnostic samples with paired tumor biopsy Supplementary Table S6. Identified mutations in FL tumors with detection in paired prediagnostic samples Supplementary Table S7. Paired tumor cohort histology & sample characteristics Supplementary Table S8. Identified mutations in paired biopsy samples Supplementary Table S9. Clonal VDJ rearrangements in paired biopsies Supplementary Table S10. Concordance analysis of paired biopsy samples Supplementary Table S11. Patient characteristics, marrow and sorting studies Supplementary Table S12. DNA and sequencing metrics for marrow and sorting studies Supplementary Table S13. Monoclonal antibodies and manufacturers Supplementary Table S14. Mutations detected in marrow and sorting studies Supplementary Table S15. Genes fully or partially covered in lymphoma-focused CAPP-Seq selector
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S15 from Tracing founder mutations in circulating and tissue-resident follicular lymphoma precursors
Supplementary Table S1. Patient and control clinical characteristics Supplementary Table S2. Sequencing metrics for FL cases & controls Supplementary Table S3. Identified mutations in EPIC FL pre-diagnostic samples Supplementary Table S4. Identified mutations in control samples Supplementary Table S5. Statistical significance for detection in prediagnostic samples with paired tumor biopsy Supplementary Table S6. Identified mutations in FL tumors with detection in paired prediagnostic samples Supplementary Table S7. Paired tumor cohort histology & sample characteristics Supplementary Table S8. Identified mutations in paired biopsy samples Supplementary Table S9. Clonal VDJ rearrangements in paired biopsies Supplementary Table S10. Concordance analysis of paired biopsy samples Supplementary Table S11. Patient characteristics, marrow and sorting studies Supplementary Table S12. DNA and sequencing metrics for marrow and sorting studies Supplementary Table S13. Monoclonal antibodies and manufacturers Supplementary Table S14. Mutations detected in marrow and sorting studies Supplementary Table S15. Genes fully or partially covered in lymphoma-focused CAPP-Seq selector
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Methods & Figures S1-S5 from Tracing founder mutations in circulating and tissue-resident follicular lymphoma precursors
Supplementary Methods and Figures S1-S5
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods & Figures S1-S5 from Tracing founder mutations in circulating and tissue-resident follicular lymphoma precursors
Supplementary Methods and Figures S1-S5
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Tracing founder mutations in circulating and tissue-resident follicular lymphoma precursors
Follicular lymphomas (FL) are characterized by BCL2 translocations, often detectable in blood years before FL diagnosis, but also observed in aging healthy individuals suggesting additional lesions are required for lymphomagenesis. We directly characterized early cooperating mutations by ultra-deep sequencing of pre-diagnostic blood and tissue specimens from 48 subjects who ultimately developed FL. Strikingly, CREBBP lysine acetyltransferase (KAT) domain mutations were the most commonly observed precursor lesions, and largely distinguished patients developing FL (14/48, 29%) from healthy adults with or without detected BCL2 rearrangements (0/13, p=0.03 and 0/20, p=0.007, respectively). CREBBP variants were detectable a median of 5.8 years before FL diagnosis, were clonally selected in FL tumors, and appeared restricted to the committed B-cell lineage. These results suggest that mutations affecting the CREBBP KAT domain are common lesions in FL cancer precursor cells (CPC), with potential for discriminating subjects at risk of developing FL or monitoring residual disease.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Tracing founder mutations in circulating and tissue-resident follicular lymphoma precursors
Follicular lymphomas (FL) are characterized by BCL2 translocations, often detectable in blood years before FL diagnosis, but also observed in aging healthy individuals suggesting additional lesions are required for lymphomagenesis. We directly characterized early cooperating mutations by ultra-deep sequencing of pre-diagnostic blood and tissue specimens from 48 subjects who ultimately developed FL. Strikingly, CREBBP lysine acetyltransferase (KAT) domain mutations were the most commonly observed precursor lesions, and largely distinguished patients developing FL (14/48, 29%) from healthy adults with or without detected BCL2 rearrangements (0/13, p=0.03 and 0/20, p=0.007, respectively). CREBBP variants were detectable a median of 5.8 years before FL diagnosis, were clonally selected in FL tumors, and appeared restricted to the committed B-cell lineage. These results suggest that mutations affecting the CREBBP KAT domain are common lesions in FL cancer precursor cells (CPC), with potential for discriminating subjects at risk of developing FL or monitoring residual disease.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S15 from Tracing founder mutations in circulating and tissue-resident follicular lymphoma precursors
Supplementary Table S1. Patient and control clinical characteristics Supplementary Table S2. Sequencing metrics for FL cases & controls Supplementary Table S3. Identified mutations in EPIC FL pre-diagnostic samples Supplementary Table S4. Identified mutations in control samples Supplementary Table S5. Statistical significance for detection in prediagnostic samples with paired tumor biopsy Supplementary Table S6. Identified mutations in FL tumors with detection in paired prediagnostic samples Supplementary Table S7. Paired tumor cohort histology & sample characteristics Supplementary Table S8. Identified mutations in paired biopsy samples Supplementary Table S9. Clonal VDJ rearrangements in paired biopsies Supplementary Table S10. Concordance analysis of paired biopsy samples Supplementary Table S11. Patient characteristics, marrow and sorting studies Supplementary Table S12. DNA and sequencing metrics for marrow and sorting studies Supplementary Table S13. Monoclonal antibodies and manufacturers Supplementary Table S14. Mutations detected in marrow and sorting studies Supplementary Table S15. Genes fully or partially covered in lymphoma-focused CAPP-Seq selector
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S15 from Tracing founder mutations in circulating and tissue-resident follicular lymphoma precursors
Supplementary Table S1. Patient and control clinical characteristics Supplementary Table S2. Sequencing metrics for FL cases & controls Supplementary Table S3. Identified mutations in EPIC FL pre-diagnostic samples Supplementary Table S4. Identified mutations in control samples Supplementary Table S5. Statistical significance for detection in prediagnostic samples with paired tumor biopsy Supplementary Table S6. Identified mutations in FL tumors with detection in paired prediagnostic samples Supplementary Table S7. Paired tumor cohort histology & sample characteristics Supplementary Table S8. Identified mutations in paired biopsy samples Supplementary Table S9. Clonal VDJ rearrangements in paired biopsies Supplementary Table S10. Concordance analysis of paired biopsy samples Supplementary Table S11. Patient characteristics, marrow and sorting studies Supplementary Table S12. DNA and sequencing metrics for marrow and sorting studies Supplementary Table S13. Monoclonal antibodies and manufacturers Supplementary Table S14. Mutations detected in marrow and sorting studies Supplementary Table S15. Genes fully or partially covered in lymphoma-focused CAPP-Seq selector
- 21 January 2024
- Published by Elsevier in The Spine Journal
- Vol. 24 (6) , 923-932
Getting what you pay for: impact of copayments on physical therapy and opioid initiation, timing, and continuation for newly diagnosed low back pain
- 21 January 2024
- Published by Elsevier in The Spine Journal
- Vol. 24 (6) , 923-932
Getting what you pay for: impact of copayments on physical therapy and opioid initiation, timing, and continuation for newly diagnosed low back pain
- Open Access
- 2 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods & Figures S1-S5 from Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors
Supplementary Methods and Figures S1-S5
- 2 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods & Figures S1-S5 from Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors
Supplementary Methods and Figures S1-S5